Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Breast Neoplasms 6Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Recurrence 1Neoplasms 1Carcinosarcoma 1Carcinoma, Squamous Cell 1Carcinoma 1Brenner Tumor 1Anus Neoplasms 1

Interventions

pembrolizumab 3Paclitaxel 3Carboplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1olaparib 1lenvatinib 1larotrectinib 1ipatasertib 1erdafitinib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Taxes 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Endometrial Neoplasms × Paclitaxel × Clear all
NCT04269200 2026-06-01

DUO-E

AstraZeneca

Phase 3 Active not recruiting
805 enrolled 18 charts 1 FDA
Gynecologic

Endometrial Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
813 enrolled 16 charts 1 FDA
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Eisai Inc.

Phase 3 Completed
827 enrolled 34 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡